{"id":3691,"date":"2026-09-04T18:08:10","date_gmt":"2026-09-04T18:08:10","guid":{"rendered":"https:\/\/indiamedicine.org\/?p=3691"},"modified":"2026-09-04T18:08:10","modified_gmt":"2026-09-04T18:08:10","slug":"iphex-2026-600-global-delegates-india-pharma-sector","status":"publish","type":"post","link":"https:\/\/indiamedicine.org\/?p=3691","title":{"rendered":"iPHEX 2026: 600+ Global Delegates Set to Source from India&#8217;s Pharma Sector"},"content":{"rendered":"\n\n<h2 class=\"wp-block-heading\">What This Means for Buyers of Indian Generic Medicines<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Evaluate multiple Indian generic medicine suppliers in a single venue<\/li>\n<li>Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers<\/li>\n<li>Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and anti-infective medicines<\/li>\n<li>Establish long-term supply relationships with verified Indian pharma exporters<\/li>\n<\/ul>\n\n\n\n\n<h2 class=\"wp-block-heading\">How to Find Verified Indian Pharma Suppliers Beyond Trade Shows<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">While trade shows like iPHEX provide excellent networking opportunities, ongoing sourcing requires reliable, continuously updated supplier directories. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a> \u2014 a curated resource for buyers seeking trusted Indian generic medicine partners.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Source: BioSpectrum India, September 3, 2026 (iPHEX 2026 overseas delegate coverage); Express Pharma, June 9, 2026 (Piyush Goyal USD 120 billion pharma sector target); The Economic Times, August 13, 2026 (Q1 FY27 pharma export performance). Details sourced via Google News RSS as of September 4, 2026.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">India&#8217;s Pharma Export Trajectory in 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical exports have shown strong momentum throughout 2026. Drug formulations and biologicals have kept the export sector healthy through Q1 FY27, as reported by The Economic Times in August 2026. The broader context includes India&#8217;s pushing for expanded market access in emerging markets such as Argentina and Brazil, per recent CDSCO and Pharmexcil initiatives. The iPHEX platform is positioned to accelerate these bilateral trade relationships.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Evaluate multiple Indian generic medicine suppliers in a single venue<\/li>\n<li>Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers<\/li>\n<li>Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and anti-infective medicines<\/li>\n<li>Establish long-term supply relationships with verified Indian pharma exporters<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">How to Find Verified Indian Pharma Suppliers Beyond Trade Shows<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>While trade shows like iPHEX provide excellent networking opportunities, ongoing sourcing requires reliable, continuously updated supplier directories. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a> \u2014 a curated resource for buyers seeking trusted Indian generic medicine partners.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Source: BioSpectrum India, September 3, 2026 (iPHEX 2026 overseas delegate coverage); Express Pharma, June 9, 2026 (Piyush Goyal USD 120 billion pharma sector target); The Economic Times, August 13, 2026 (Q1 FY27 pharma export performance). Details sourced via Google News RSS as of September 4, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">Why iPHEX Matters for Global Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international buyers seeking reliable Indian generic medicines, events like iPHEX serve as a critical verification channel. Meeting manufacturers face-to-face, inspecting product portfolios, and discussing quality standards \u2014 including WHO-GMP compliance and CDSCO regulatory adherence \u2014 in person adds a layer of trust that remote sourcing simply cannot replicate. The event also provides access to a broad spectrum of therapeutic segments, from cardiovascular and anti-diabetic generics to specialty biotech products.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">India&#8217;s Pharma Export Trajectory in 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical exports have shown strong momentum throughout 2026. Drug formulations and biologicals have kept the export sector healthy through Q1 FY27, as reported by The Economic Times in August 2026. The broader context includes India&#8217;s pushing for expanded market access in emerging markets such as Argentina and Brazil, per recent CDSCO and Pharmexcil initiatives. The iPHEX platform is positioned to accelerate these bilateral trade relationships.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Evaluate multiple Indian generic medicine suppliers in a single venue<\/li>\n<li>Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers<\/li>\n<li>Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and anti-infective medicines<\/li>\n<li>Establish long-term supply relationships with verified Indian pharma exporters<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">How to Find Verified Indian Pharma Suppliers Beyond Trade Shows<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>While trade shows like iPHEX provide excellent networking opportunities, ongoing sourcing requires reliable, continuously updated supplier directories. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a> \u2014 a curated resource for buyers seeking trusted Indian generic medicine partners.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Source: BioSpectrum India, September 3, 2026 (iPHEX 2026 overseas delegate coverage); Express Pharma, June 9, 2026 (Piyush Goyal USD 120 billion pharma sector target); The Economic Times, August 13, 2026 (Q1 FY27 pharma export performance). Details sourced via Google News RSS as of September 4, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">The Numbers Behind the Event<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Pharmexcil, operating under the Department of Pharmaceuticals, Government of India, has set an ambitious target of facilitating USD 1.4 billion in export business through iPHEX 2026. With over 600 overseas delegates confirmed, the event reflects growing international confidence in India&#8217;s generics manufacturing ecosystem. India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, according to Commerce and Industry Minister Piyush Goyal, who made the statement in June 2026 as reported by Express Pharma.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">Why iPHEX Matters for Global Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international buyers seeking reliable Indian generic medicines, events like iPHEX serve as a critical verification channel. Meeting manufacturers face-to-face, inspecting product portfolios, and discussing quality standards \u2014 including WHO-GMP compliance and CDSCO regulatory adherence \u2014 in person adds a layer of trust that remote sourcing simply cannot replicate. The event also provides access to a broad spectrum of therapeutic segments, from cardiovascular and anti-diabetic generics to specialty biotech products.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">India&#8217;s Pharma Export Trajectory in 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical exports have shown strong momentum throughout 2026. Drug formulations and biologicals have kept the export sector healthy through Q1 FY27, as reported by The Economic Times in August 2026. The broader context includes India&#8217;s pushing for expanded market access in emerging markets such as Argentina and Brazil, per recent CDSCO and Pharmexcil initiatives. The iPHEX platform is positioned to accelerate these bilateral trade relationships.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Evaluate multiple Indian generic medicine suppliers in a single venue<\/li>\n<li>Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers<\/li>\n<li>Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and anti-infective medicines<\/li>\n<li>Establish long-term supply relationships with verified Indian pharma exporters<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">How to Find Verified Indian Pharma Suppliers Beyond Trade Shows<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>While trade shows like iPHEX provide excellent networking opportunities, ongoing sourcing requires reliable, continuously updated supplier directories. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a> \u2014 a curated resource for buyers seeking trusted Indian generic medicine partners.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Source: BioSpectrum India, September 3, 2026 (iPHEX 2026 overseas delegate coverage); Express Pharma, June 9, 2026 (Piyush Goyal USD 120 billion pharma sector target); The Economic Times, August 13, 2026 (Q1 FY27 pharma export performance). Details sourced via Google News RSS as of September 4, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What Is iPHEX 2026?<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>iPHEX (International Pharmaceutical Expo) is India&#8217;s flagship platform for connecting domestic manufacturers with global buyers. It serves as a B2B matchmaking hub where Indian generic medicine producers, biotech firms, and API (Active Pharmaceutical Ingredient) manufacturers meet procurement heads from regulated and semi-regulated markets across the globe. The 12th edition marks a significant expansion in scale compared to previous years.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">The Numbers Behind the Event<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Pharmexcil, operating under the Department of Pharmaceuticals, Government of India, has set an ambitious target of facilitating USD 1.4 billion in export business through iPHEX 2026. With over 600 overseas delegates confirmed, the event reflects growing international confidence in India&#8217;s generics manufacturing ecosystem. India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, according to Commerce and Industry Minister Piyush Goyal, who made the statement in June 2026 as reported by Express Pharma.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">Why iPHEX Matters for Global Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international buyers seeking reliable Indian generic medicines, events like iPHEX serve as a critical verification channel. Meeting manufacturers face-to-face, inspecting product portfolios, and discussing quality standards \u2014 including WHO-GMP compliance and CDSCO regulatory adherence \u2014 in person adds a layer of trust that remote sourcing simply cannot replicate. The event also provides access to a broad spectrum of therapeutic segments, from cardiovascular and anti-diabetic generics to specialty biotech products.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">India&#8217;s Pharma Export Trajectory in 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical exports have shown strong momentum throughout 2026. Drug formulations and biologicals have kept the export sector healthy through Q1 FY27, as reported by The Economic Times in August 2026. The broader context includes India&#8217;s pushing for expanded market access in emerging markets such as Argentina and Brazil, per recent CDSCO and Pharmexcil initiatives. The iPHEX platform is positioned to accelerate these bilateral trade relationships.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Evaluate multiple Indian generic medicine suppliers in a single venue<\/li>\n<li>Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers<\/li>\n<li>Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and anti-infective medicines<\/li>\n<li>Establish long-term supply relationships with verified Indian pharma exporters<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">How to Find Verified Indian Pharma Suppliers Beyond Trade Shows<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>While trade shows like iPHEX provide excellent networking opportunities, ongoing sourcing requires reliable, continuously updated supplier directories. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a> \u2014 a curated resource for buyers seeking trusted Indian generic medicine partners.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Source: BioSpectrum India, September 3, 2026 (iPHEX 2026 overseas delegate coverage); Express Pharma, June 9, 2026 (Piyush Goyal USD 120 billion pharma sector target); The Economic Times, August 13, 2026 (Q1 FY27 pharma export performance). Details sourced via Google News RSS as of September 4, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content --><!-- \/wp:heading --><!-- wp:post-content --><!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical export landscape is preparing for a landmark event. The 12th edition of iPHEX 2026 \u2014 India&#8217;s largest international pharmaceutical exhibition \u2014 is set to bring together over 600 overseas business delegates to engage with Indian pharma companies, as reported by BioSpectrum India on September 3, 2026. Organized by the Pharmaceuticals Export Promotion Council (Pharmexcil), the event targets USD 1.4 billion in export business opportunities.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What Is iPHEX 2026?<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>iPHEX (International Pharmaceutical Expo) is India&#8217;s flagship platform for connecting domestic manufacturers with global buyers. It serves as a B2B matchmaking hub where Indian generic medicine producers, biotech firms, and API (Active Pharmaceutical Ingredient) manufacturers meet procurement heads from regulated and semi-regulated markets across the globe. The 12th edition marks a significant expansion in scale compared to previous years.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">The Numbers Behind the Event<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Pharmexcil, operating under the Department of Pharmaceuticals, Government of India, has set an ambitious target of facilitating USD 1.4 billion in export business through iPHEX 2026. With over 600 overseas delegates confirmed, the event reflects growing international confidence in India&#8217;s generics manufacturing ecosystem. India&#8217;s pharma sector is projected to reach USD 120 billion in value by 2031, according to Commerce and Industry Minister Piyush Goyal, who made the statement in June 2026 as reported by Express Pharma.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">Why iPHEX Matters for Global Buyers<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For international buyers seeking reliable Indian generic medicines, events like iPHEX serve as a critical verification channel. Meeting manufacturers face-to-face, inspecting product portfolios, and discussing quality standards \u2014 including WHO-GMP compliance and CDSCO regulatory adherence \u2014 in person adds a layer of trust that remote sourcing simply cannot replicate. The event also provides access to a broad spectrum of therapeutic segments, from cardiovascular and anti-diabetic generics to specialty biotech products.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">India&#8217;s Pharma Export Trajectory in 2026<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>India&#8217;s pharmaceutical exports have shown strong momentum throughout 2026. Drug formulations and biologicals have kept the export sector healthy through Q1 FY27, as reported by The Economic Times in August 2026. The broader context includes India&#8217;s pushing for expanded market access in emerging markets such as Argentina and Brazil, per recent CDSCO and Pharmexcil initiatives. The iPHEX platform is positioned to accelerate these bilateral trade relationships.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">What This Means for Buyers of Indian Generic Medicines<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\">\n<li>Evaluate multiple Indian generic medicine suppliers in a single venue<\/li>\n<li>Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers<\/li>\n<li>Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and anti-infective medicines<\/li>\n<li>Establish long-term supply relationships with verified Indian pharma exporters<\/li>\n<\/ul>\n<!-- \/wp:list -->\n\n<!-- wp:heading -->\n<!-- wp:heading {\"level\":2} -->\n<h2 class=\"wp-block-heading\">How to Find Verified Indian Pharma Suppliers Beyond Trade Shows<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>While trade shows like iPHEX provide excellent networking opportunities, ongoing sourcing requires reliable, continuously updated supplier directories. For a list of verified and reliable pharmaceutical distributors, refer to the <a href=\"https:\/\/indiamedicine.org\/?page_id=1454\">IMSDA&#8217;s verified member directory<\/a> \u2014 a curated resource for buyers seeking trusted Indian generic medicine partners.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:separator -->\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n<!-- \/wp:separator -->\n\n<!-- wp:paragraph -->\n<p><em>Source: BioSpectrum India, September 3, 2026 (iPHEX 2026 overseas delegate coverage); Express Pharma, June 9, 2026 (Piyush Goyal USD 120 billion pharma sector target); The Economic Times, August 13, 2026 (Q1 FY27 pharma export performance). Details sourced via Google News RSS as of September 4, 2026.<\/em><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>For more information, contact IMSDA at contact@indiamedicine.org.<\/p>\n<!-- \/wp:paragraph --><!-- \/wp:post-content -->","protected":false},"excerpt":{"rendered":"<p>What This Means for Buyers of Indian Generic Medicines For healthcare procurement professionals, distributors, and pharmacy chain buyers, iPHEX 2026 represents a concentrated opportunity to: Evaluate multiple Indian generic medicine suppliers in a single venue Discuss WHO-GMP and CDSCO compliance documentation directly with manufacturers Explore pricing structures for high-volume generic categories including cardiovascular, diabetes, and [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[41,48,29,49],"class_list":["post-3691","post","type-post","status-publish","format-standard","hentry","category-news","tag-fda","tag-generic-medicines","tag-india-pharmacy","tag-indian-pharma","entry"],"_links":{"self":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3691"}],"version-history":[{"count":0,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=\/wp\/v2\/posts\/3691\/revisions"}],"wp:attachment":[{"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiamedicine.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}